3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
11
Triple Negative Breast Neoplasms
8
Neoplasm Metastasis
6
Stomach Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Renal Cell
4
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Melanoma
3
Prostatic Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Hematologic Neoplasms
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Small Cell Lung Carcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peritoneal Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Lymphoma, Non-Hodgkin
1
Interventions
pembrolizumab
24
Nivolumab
7
Early Intervention, Educational
7
Methods
6
durvalumab
5
aldesleukin
5
Trastuzumab
5
Paclitaxel
5
Fulvestrant
5
Carboplatin
5
atezolizumab
4
Surveys and Questionnaires
4
Patient Navigation
4
Docetaxel
4
Cyclophosphamide
4
Biopsy
4
fludarabine
3
Mass Screening
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Interleukin-2
3
Gene Expression Profiling
3
Fluorouracil
3
Educational Status
3
Bevacizumab
3
tremelimumab
2
spartalizumab
2
sargramostim
2
palbociclib
2
fludarabine phosphate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Leucovorin
×
Breast
×
Clear all
NCT05891171
2026-03-31
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled